Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance - Top-Institutions - MDSpire

Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance

  • By

  • Difei Yu

  • Jiarun Tang

  • Yu Zhang

  • Ke Hu

  • Jing Qing

  • Jiamo Zhang

  • June 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Urology
    • Oncology

  • #2

    Keck Medicine of USC / USC Norris Comprehensive Cancer Center
    Keck Medicine of USC / USC Norris Comprehensive Cancer Center

    Los Angeles, California

    Key Differentiators

    • Urology
    • Oncology

  • #3

    Fox Chase Cancer Center
    Fox Chase Cancer Center

    Philadelphia, Pennsylvania

    Key Differentiators

    • Urology
    • Oncology

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Urology
    • Oncology

  • #5

    University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

    Key Differentiators

    • Urology
    • Oncology

Original Source(s)

Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance

  • by Difei Yu, Jiarun Tang, Yu Zhang, Ke Hu, Jing Qing, Jiamo Zhang

  • June 2, 2026

Related Content

Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential

Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer